Patent · US Active

Compounds for enzyme inhibition

US7417042B2 · kind B2 · utility

53Cited by
14References
37Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 8, 2005
Grant dateAug 26, 2008
Priority date
Expiry dateOct 1, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.